SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as its CEO's recent "curative" claims for the GPS cancer therapy spark fervent debate and massive bullish sentiment among investors. The community is focused on the impending Phase 3 trial readout and a potential short squeeze, while also heavily contesting bearish arguments fueled by high short interest and questions of valuation.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp is trending amidst intense volatility driven by escalating geopolitical tensions in the Middle East, with ongoing conflict impacting oil supply routes and leading to wildly fluctuating crude prices. The community is sharply divided between those anticipating a significant short squeeze in oil-related stocks and others warning of a rapid correction, especially following a recent stock offering.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as it secures a spot in the White House-backed eIPP for early U.S. air taxi operations and launches Uber Air services in Dubai, intensifying community discussion around its accelerating path to commercialization and FAA certification amidst strong partnerships and recent revenue beats.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

Hewlett Packard Enterprise is trending following its Q1 FY26 earnings, which beat EPS estimates and raised full-year guidance, driven by robust networking segment performance following the Juniper acquisition and growing demand for AI systems. The community is actively discussing the substantial increase in networking revenue and a significant AI server backlog, leading to optimistic price targets, while some debate its long-term margin expansion against competitors.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is trending due to breakthrough ASH data for NXC-201, which showed high complete response rates in AL amyloidosis and led to an oversubscribed institutional offering. The community is buzzing about strategic hires signaling imminent BLA preparation, broader pipeline expansion into autoimmune diseases, and recent analyst coverage with significant price targets, all pointing to a potential re-rating as the company progresses through regulatory milestones.

SoftBank Group Corp. operates as a holding company which engages in the management of its group companies. It operates through the following segments: SoftBank Vision Fund, SoftBank, Arm, Brightstar, and Others. The SoftBank Vision Fund segment engages in the investment business. The SoftBank segment provides mobile communication, broadband, and telecom services in Japan. The Arm segment designs microprocessors and develops software technologies. The Brightstar segment engages in the distribution of mobile devices overseas. The Others segment includes the smartphone payments business, alternative investment business, fund business in Latin America and the operation of baseball teams. The company was founded by Masayoshi Son on September 3, 1981 and is headquartered in Tokyo, Japan.

SoftBank Group Corp. - ADR

SoftBank Corp.

SoftBank is trending due to its aggressive "all-in" bet on AI infrastructure, marked by massive investments in OpenAI, strategic acquisitions like DigitalBridge and Ampere Computing, and plans for new AI data centers, sparking community discussions on its bold, high-risk strategy to become an AI powerhouse.

Talkspace, Inc. engages in the operation and development of a technology platform used in connecting patients to licensed mental health professionals through messaging, video, and audio. The company was founded by Frank Roni and Frank Oren in 2012 and is headquartered in New York, NY.

Talkspace Inc

Talkspace is trending after Universal Health Services announced its acquisition for $5.25 per share, with many investors celebrating solid returns, though a significant portion of the community feels the company was sold too cheaply and below its true potential.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is trending with increased accessibility from recent major exchange listings, exciting the community about its rapidly developing AI agent utility and strong revenue generation within the growing Base ecosystem, with many anticipating significant market cap growth.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as extreme volatility engulfs oil markets, fueled by escalating Middle East tensions, reports of tightening supply from Gulf nations, and critical uncertainty around the Strait of Hormuz. The community is sharply divided between those anticipating higher prices due to ongoing supply risks and others expecting a significant pullback as global powers discuss oil reserve releases and potential de-escalation.

Hyperliquid is a performant L1 optimized from the ground up. The vision is a fully onchain open financial system with user built applications interfacing with performant native components, all without compromising end user experience.   The Hyperliquid L1 is performant enough to operate an entire ecosystem of permissionless financial applications – every order, cancel, trade, and liquidation happens transparently on-chain with block latency &lt;1 second. The chain currently supports 100k orders / second.  The Hyperliquid L1 uses a custom consensus algorithm called HyperBFT which is heavily inspired by Hotstuff and its successors. Both the algorithm and networking stack are optimized from the ground up to support the L1.   The flagship native application is a fully onchain order book perpetuals exchange, the Hyperliquid DEX. Further developments include a native token standard, spot trading, permissionless liquidity, etc.

Hype

HYPE is trending as its Hyperliquid DEX continues to capture significant trading volume, outperforming major cryptos with robust deflationary tokenomics, leading the community to hail it as 'the house of all finance' and a potential safe haven in volatile markets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ESSA Announces Completion of Arrangement with XenoTherapeutics

ESSA Announces Completion of Arrangement with XenoTherapeutics ESSA Announces Completion of Arrangement with XenoTherapeutics PR Newswire SOUTH SAN FRANCISCO, Calif., USA and VANCOUVER, BC, Canada...

Shares of Essa Pharma, Inc. (<a class="mention" data-mention="$EPIX" data-symbol-id="EPIX" href="https://stocktwits.com/symbol/EPIX" target="_blank">$EPIX</a>) plummeted 70% on Friday morning after the company announced it would end its Phase 2 study of masofaniten, its lead drug candidate for prostate cancer.&nbsp;Essa’s decision follows an interim analysis indicating that the study was unlikely to meet its primary endpoint, a move aimed at prioritizing patient benefit and safety.&nbsp;CEO David Parkinson noted that the trial’s emerging efficacy profile for masofaniten, when combined with enzalutamide, was insufficient to justify continuation.Richard Glickman, Chairman of Essa’s Board, confirmed that the company is shifting focus to preserve capital, initiating a strategic review to explore options for maximizing shareholder value.&nbsp;JonesResearch analyst Soumit Roy downgraded Essa Pharma to ‘Hold’ from ‘Buy,’ saying “we were wrong in our assessment of masofaniten's potential.”&nbsp;Roy also anticipates the stock to trade at a 40%-50% discount to its cash per share, currently $2.64, until further guidance from management.<figure class="image"><a href="https://stocktwits.com/symbol/EPIX"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_01_at_9_42_09_AM_25b012ad7e.png" alt="Screenshot 2024-11-01 at 9.42.09 AM.png" width="1314" height="320"></a><figcaption>EPIX sentiment and message volume on Nov. 1 as of 9:45 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment turned ‘extremely bearish’ (9/100), the lowest in a year, with several users questioning the company’s pipeline viability.&nbsp;Some predicted a continued slide, with expectations of the stock trading below $1 as large shareholders exit their positions for tax write-offs.<stembedurl>https://stocktwits.com/StarLord13/message/590874905</stembedurl><stembedurl>https://stocktwits.com/elmono/message/590874567</stembedurl>Essa’s stock is down about 20% year-to-date as of Thursday’s close.&nbsp;Shares of the company are currently trading at their lowest level in over two years.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next: <a href="https://stocktwits.com/news-articles/markets/equity/wayfair-stock-rises-on-q3-earnings-beat/cJEYA3ARBk">Wayfair Thrills Retail Crowd As Stock Soars Premarket On Big Q3 Earnings Beat</a>

Shares of Essa Pharma are currently trading at their lowest level in over two years.

Essa Pharma Stock Crashes After Lead Drug Candidate Trial Flops: Retail Hopes Fade

Richard Glickman, Chairman of Essa’s Board, confirmed that the company is shifting focus to preserve capital, initiating a strategic review

Equity

Richard Glickman, Chairman of Essa’s Board, confirmed that the company is shifting focus to preserve capital, initiating a strategic review


ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It engages in the business of developing small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

EPIX
Essa Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest EPIX News

EPIXEssa Pharma Inc